RESUMO
Ten patients (6 to 27 years of age) who had severe pancreatic exocrine insufficiency due to cystic fibrosis were studied to determine whether cimetidine would improve dietary fat and nitrogen absorption. When a constant diet was consumed and oral pancreatic enzymes were administered, the addition of cimetidine (150 or 200 mg taken orally one-half hour before meals) signficantly reduced fecal fat excretion from 25.3 +/- 2.9 to 17.3 +/- 2.1 gm/24 hours and fecal nitrogen excretion from 4.5 +/- 0.6 to 3.4 +/- 0.5 gm/24 hours (P less than 0.05). Lower doses of cimetidine resulted in less significant reductions of steatorrhea and azotorrhea. Cimetidine may be a useful adjunct to oral pancreatic enzyme therapy in patients with cystic fibrosis who continue to have steatorrhea and azotorrhea with enzyme therapy alone.
Assuntos
Cimetidina/uso terapêutico , Fibrose Cística/complicações , Guanidinas/uso terapêutico , Síndromes de Malabsorção/tratamento farmacológico , Adolescente , Adulto , Doença Celíaca/tratamento farmacológico , Doença Celíaca/etiologia , Criança , Cimetidina/sangue , Fibrose Cística/sangue , Quimioterapia Combinada , Feminino , Humanos , Síndromes de Malabsorção/sangue , Síndromes de Malabsorção/etiologia , Masculino , Extratos Pancreáticos/uso terapêutico , Pancreatina/uso terapêuticoRESUMO
The absorption of digoxin in cystic fibrosis was evaluated in 16 subjects by assessing the relationship between dosage expressed in mug/kg/day and serum digoxin concentration. The results indicate that the same relationship exists between maintenance dosage and serum levels in these patients and in patients without cystic fibrosis. Thus, no evidence of impaired absorption was found.